Dear Editor, the publication on “Wilm's tumor-1 (WT1) rs16754 polymorphism and clinical outcome in acute myeloid leukemia.” is very interesting [1]. Ramzi et al. noted that “WT1 rs16754 polymorphism may be a reliable and independent prognostic factor [1].” In fact, the WT1 rs16754 polymorphism is proposed as an important prognostic marker for leukemia [2]. The application in the present study might be expected. However, there can also be interference effects of other polymorphisms (such as MDM2 [3] and long non-coding RNA GAS5 polymorphism [4]) that were not investigated that might modified the value of WT1 rs16754 polymorphism test. The single polymorphism study might limit its application in clinical usage for prognosis predicting for the leukemia patients.

Conflict of interest: None

References